Dear Sir,
We have read with great interest the article recently published by Guedj et al., titled 18F-FDG brain PET hypometabolism in patients with long COVID [1]. We recently proposed that PET imaging versatility might hold the key for understanding pathophysiological changes in the brain of COVID-19 patients [2]. The article by Guedj and colleagues is a great demonstration of how powerful PET imaging can be in this regard.
This article provides evidence that COVID-19 patients with persistent functional complaints, more than 3 weeks after the first symptoms, present continuous 18F-FDG PET hypometabolism in multiple brain regions, including the olfactory gyrus, hippocampus and cerebellum.
Few months ago, small-scale studies provided initial evidence of brain glucose hypometabolism in COVID-19 individuals [3, 4] sharing similar findings concerning the hypometabolic brain regions, such as the pre-frontal cortex and the gyrus rectus. Our letter intends to raise awareness on (1) the biological interpretation of decreased brain 18F-FDG PET signal in COVID-19 and (2) potential sequelae due to brain glucose hypometabolism in long COVID.
Cellular origins of 18F-FDG PET hypometabolism in COVID-19
In 1977, Sokoloff developed and validated a kinetic model for estimating brain glucose metabolism using PET 18F-FDG [5]. Sokoloff’s two-tissue compartment model comprises 18F-FDG in plasma, free 18F-FDG and phosphorylated 18F-FDG in brain tissue [5]. For more than 4 decades, the biological interpretation of brain PET 18F-FDG signal was considered a direct index of neuronal activity [6]. Nevertheless, over the last years, a more integrative view in which astrocytes, an abundant type of glial cells, are also prominent contributors to the 18F-FDG PET signal has emerged [7]. Indeed, it seems that astrocytes substantially contribute to 18F-FDG PET signal [8,9,10]. Moreover, it is known that astrocytes play pivotal roles in the brain defence against peripheral inflammatory changes [11]. Guedj and colleagues [1] mentioned that acute systemic inflammation and SARS-CoV-2 neurotropism could be related to brain inflammatory alterations. Complementary, other groups identified signs of reactive astrogliosis in post-mortem tissue of COVID-19 patients [12], in cellular models and in brain organoids [13]. In keeping with this, one could not neglect astrocyte dysfunction as the possible cellular origin of brain 18F-FDG PET hypometabolism in COVID-19. In vivo brain imaging of COVID-19 individuals using specific PET radiotracers targeting reactive astrocytes (e.g. 11C-DED and 11C-BU99008) could help settling this matter.
Persistent brain hypometabolism measured by 18F-FDG PET - a risk for developing neurodegenerative diseases
While the cellular origins of brain 18F-FDG PET hypometabolism in COVID-19 remain to be defined, it seems clear that we are dealing with persistent synaptic dysfunction. Guedj et al. [1] demonstrated that multiple brain regions are hypometabolic in long COVID. In addition, it seems that there is a link between clinical manifestations and regional glucose hypometabolism. For instance, decreased glucose consumption in the cerebellum was linked to hyposmia/anosmia and cognitive impairment. Another recent study followed up the 18F-FDG brain profile of seven patients in the early phase of infection, 1 month and 6 months after COVID-19 onset. Interestingly, the abnormal cognitive function associated with pre-frontal cortex hypometabolism persisted in all patients for ~6 months [14]. Remarkably, 18F-FDG brain hypometabolism in the pre-frontal cortex is present in multiple neurodegenerative disorders [15] and neuropsychiatric conditions [16], sometimes even preceding the first symptoms.
Thus, the cellular origins of COVID-19 18F-FDG PET hypometabolism in short- and long-term scenario remain to be explored, with mounting evidence suggesting an astroglial contribution. Furthermore, persistent 18F-FDG PET hypometabolism in long COVID patients should be carefully monitored in terms of potential sequelae, such as the development of brain disorders.
References
Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05215-4.
Fontana IC, Bongarzone S, Gee A, Souza DO, Zimmer ER. PET imaging as a tool for assessing COVID-19 brain changes. Trends Neurosci. 2020;43:935–8. https://doi.org/10.1016/j.tins.2020.10.010.
Delorme C, Paccoud O, Kas A, Hesters A, Bombois S, Shambrook P, et al. Covid-19-related encephalopathy: a case series with brain FDG-PET/CT findings. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14478.
Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, Raad N, Haseli S. (18) FDG PET/CT scan reveals hypoactive orbitofrontal cortex in anosmia of COVID-19. Acad Radiol. 2020;27:1042–3. https://doi.org/10.1016/j.acra.2020.04.030.
Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897–916. https://doi.org/10.1111/j.1471-4159.1977.tb10649.x.
Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49:390–8. https://doi.org/10.2967/jnumed.107.045385.
Magistretti PJ, Pellerin L. The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. Mol Psychiatry. 1996;1:445–52.
Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI, et al. [(18)F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20:393–5. https://doi.org/10.1038/nn.4492.
Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte biomarkers in Alzheimer’s disease. Trends Mol Med. 2019;25:77–95. https://doi.org/10.1016/j.molmed.2018.11.006.
Stoessl AJ. Glucose utilization: still in the synapse. Nat Neurosci. 2017;20:382–4. https://doi.org/10.1038/nn.4513.
Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci. 2015;16:249–63. https://doi.org/10.1038/nrn3898.
Matschke J, Lütgehetmann M, Hagel C, Sperhake PJP, Schröder AS, Edler C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet. 2020. https://doi.org/10.1016/S1474-4422(20)30308-2.
Wang C, Zhang M, Garcia G Jr, Tian E, Cui Q, Chen X, et al. ApoE-isoform-dependent SARS-CoV-2 neurotropism and cellular response. Cell Stem Cell. 2021;28:331–42 e5. https://doi.org/10.1016/j.stem.2020.12.018.
Kas A, Soret M, Pyatigoskaya N, Habert MO, Hesters A, Le Guennec L, et al. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-020-05178-y.
Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486–510. https://doi.org/10.1007/s00259-005-1762-7.
Lehrer DS, Christian BT, Mantil J, Murray AC, Buchsbaum BR, Oakes TR, et al. Thalamic and prefrontal FDG uptake in never medicated patients with schizophrenia. Am J Psychiatry. 2005;162:931–8. https://doi.org/10.1176/appi.ajp.162.5.931.
Funding
I.C.F. and D.O.S. are supported by CAPES [88887.185806/2018-00]. DGS is supported by CNPQ [152189/2020-3]. LP is supported by Inserm and Université de Poitiers. D.O.S. is supported by CNPQ/INCT [465671/2014-4], CNPQ/ZIKA [440763/2016-9], CNPQ/FAPERGS/PRONEX [16/2551-0000475-7], FAPERGS [19/2551-0000700-0], CAPES [88887.507218/2020-00] [88887.507161/2020-00]. E.R.Z. is supported by CNPq [435642/2018-9] [312410/2018-2] and Instituto Serrapilheira [Serra-1912-31365].
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
This article is part of the Topical Collection on Letter to the Editor
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fontana, I.C., Souza, D.G., Pellerin, L. et al. About the source and consequences of 18F-FDG brain PET hypometabolism in short and long COVID-19. Eur J Nucl Med Mol Imaging 48, 2674–2675 (2021). https://doi.org/10.1007/s00259-021-05342-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-021-05342-y